Increased methylation of the MEG3-DMR and related loss of MEG3 expression has been observed in several human cancers, such as pituitary and renal cell cancers and multiple myeloma (Zhao et al., 2005; Kawakami et al., 2006; Benetatos et al., 2008) to name a few (further reviewed by Benetatos et al., 2011). Here, MEG3 is linked to AL amyloidosis.